It’s been a dynamic year for GLP-1s, with employers and their partners deploying a range of strategies to manage costs and utilization. Despite these efforts, employers have once again identified GLP-1s as a top cost driver and many are seeking greater transparency, more impactful cost reduction and strategic alignment from their partners. 

Join us on September 25 for a panel featuring representatives from CVS Caremark, Evernorth, Eli Lilly, and Weight Watchers addressing the questions employers are asking most: 

- What steps are being taken towards transparent and sustainable pharmacy pricing for this category of medications? 

- How can employers actively lead to re-shape the market for GLP-1 medications, including savings resulting from improved patient health 

- Are there any lessons learned or changes planned for the future?